CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Autor: Beverage JN; Clinical Pharmacology Research Core, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, Maryland, USA., Sissung TM, Sion AM, Danesi R, Figg WD
Jazyk: angličtina
Zdroj: Journal of pharmaceutical sciences [J Pharm Sci] 2007 Sep; Vol. 96 (9), pp. 2224-31.
DOI: 10.1002/jps.20892
Abstrakt: The cytochrome P450 2D6 (CYP2D6) is an enzyme known to metabolize a variety of xenobiotics and drugs. Inter-individual variation in the metabolic capacity of this enzyme has been extensively studied and associations with genotype have been established. Genetic polymorphisms have been grouped as nonfunctional, reduced function, functional, and multiplication alleles phenotypically. Individuals carrying these alleles are presumed to correspond to poor, intermediate, extensive, and ultrarapid metabolizers (UM), respectively. Tamoxifen has been shown to be metabolized by CYP2D6 to the more potent metabolite endoxifen. Poor metabolizers (PM) of tamoxifen have lower levels of endoxifen and poorer clinical outcomes as compared to extensive metabolizers (EM). Here, we will provide an overview of the history and application of CYP2D6 pharmacogenetics, and will discuss the clinical implications of recent developments relating to the involvement of CYP2D6 in tamoxifen treatment.
((c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.)
Databáze: MEDLINE
Externí odkaz: